Clinical Trials Directory

Trials / Completed

CompletedNCT00374985

Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal Junction

Prospective, Open, Multicentre Phase I/II Study to Evaluate the Safety and Efficacy of a Neoadjuvant Radiochemotherapy With Docetaxel and Oxalipaltin in Patients With Adenocarcinoma of the Gastric-oesophageal Junction

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
25 (actual)
Sponsor
Johannes Gutenberg University Mainz · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the dose limiting toxicity and the maximum tolerable dose of the radiochemotherapy with Docetaxel and Oxaliplatin in patients with adenocarcinoma of the gastric-oesophageal junction.

Detailed description

Radiotherapy starts on day 1 of chemotherapy after the application of Docetaxel and Oxaliplatin and will be administered in single doses of 1.8 Gy once daily and five times a week for 5 weeks. In the sixth treatment week a boost of 3 further radiations with 1.8 Gy will be applied. Simultaneous chemotherapy: Initially, in part A of the study the maximum tolerable dose (MTD) for the simultaneous chemotherapy will be identified with a 3-step dose escalation scheme: Level 1: Docetaxel: 20 mg/m2 Oxaliplatin 40 mg/m2 i.v., Level 2: Docetaxel: 20 mg/m2 Oxaliplatin 50 mg/m2 i.v., Level 3: Docetaxel: 25 mg/m2 Oxaliplatin 50 mg/m2 i.v., The treatment starts with 3 patients in level 1. If no dose limiting toxicities appear, it will be switched to dose level 2. The same applies for the switch from level 2 to level 3. If a DLT appears on one level, a further 3 patients will be treated within this dose level. If in one level at least 2 of 6 patients show DLT, the subjacent level will be defined as the maximum tolerable dose (MTD).

Conditions

Interventions

TypeNameDescription
DRUGDocetaxel, Oxaliplatinweekly doses
PROCEDURERadiotherapyregular fractions

Timeline

Start date
2005-10-01
Primary completion
2013-09-01
Completion
2013-09-01
First posted
2006-09-12
Last updated
2014-12-02

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT00374985. Inclusion in this directory is not an endorsement.